1
|
Ortiz-Martínez Y, Kouamé MG, Bongomin F, Lakoh S, Henao-Martínez AF. Human African Trypanosomiasis (Sleeping Sickness)-Epidemiology, Clinical Manifestations, Diagnosis, Treatment, and Prevention. CURRENT TROPICAL MEDICINE REPORTS 2023; 10:222-234. [PMID: 38939748 PMCID: PMC11210952 DOI: 10.1007/s40475-023-00304-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/13/2023] [Indexed: 06/29/2024]
Abstract
Purpose of Review Human African Trypanosomiasis (HAT), also known as sleeping sickness, is a vector-borne parasitic neglected tropical disease (NTD) endemic in sub-Saharan Africa. This review aims to enhance our understanding of HAT and provide valuable insights to combat this significant public health issue by synthesizing the latest research and evidence. Recent Findings HAT has reached a historical < 1000 cases in 2018. In patients without neurologic symptoms and signs, the likelihood of a severe meningoencephalitic stage is deemed low, obviating the need for a lumbar puncture to guide treatment decisions using fexinidazole. Summary Both forms of the disease, gambiense HAT (gHAT) and rhodesiense HAT (rHAT), have specific epidemiology, risk factors, diagnosis, and treatment. Disease management still requires a high index of suspicion, infectious disease expertise, and specialized medical care. Essential stakeholders in health policy are critical to accomplishing the elimination goals of the NTD roadmap for 2021-2030.
Collapse
Affiliation(s)
- Yeimer Ortiz-Martínez
- Department of Internal Medicine, Universidad Industrial de Santander, Bucaramanga, Colombia
| | | | - Felix Bongomin
- Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda
| | - Sulaiman Lakoh
- College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
| | - Andrés F. Henao-Martínez
- Division of Infectious Diseases, Department of Medicine, University of Colorado, Anschutz Medical Campus, 12700 E. 19th Avenue, Mail Stop B168, Aurora, CO 80045, USA
| |
Collapse
|
2
|
Vander Kelen C, Mpanya A, Hasker E, Miaka E, Nzuzi R, Pulford J, Torr S, Perez Chacon D. Community empowerment through participation in a tsetse control project in the Democratic Republic of Congo. PLOS GLOBAL PUBLIC HEALTH 2023; 3:e0001325. [PMID: 37315036 DOI: 10.1371/journal.pgph.0001325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Accepted: 05/16/2023] [Indexed: 06/16/2023]
Abstract
Gambiense Human African Trypanosomiasis (g-HAT) is a neglected tropical disease caused by trypanosomes transmitted by tsetse flies. In 2017, a pilot community-based project was launched in three villages in DRC with the overall goal of empowering community members to control tsetse using Tiny Targets which attract and kill tsetse. In this paper, we assess the community participation process in these three pilot villages over >4 years and evaluate to what extent this resulted in the empowerment of communities. We conducted a qualitative study using a participatory research approach. Together with community members of the three pilot villages from the endemic Kwilu province, we evaluated changes in project participation, community empowerment and perception of future participation at three different time points (September 2017, September 2018 and November 2021) over a 4-year period using participatory workshops and focus group discussions (FGD). We used a thematic content approach to analyse both workshop notes and FGD transcripts. The community identified five indicators to evaluate participation: (1) Leadership & Ownership, (2) Organisation & Planning, (3) Willingness, (4) Autonomy and (5) Community Involvement. The participation experience described by community members was characterised by a rapid growth of empowerment in the first year and sustained high levels thereafter. Community participants were willing to engage in potential future projects and continue to be supported by their Tiny Target project partner. However, they identified an imbalance in the power relationship within the committee and with the Tiny Target partners that limit the extent of empowerment attained. The intervention had broader benefits of community empowerment but this was limited by perceptions of being part of wider "top down" programme and by stakeholders attitude toward community participation. If empowerment is to be an important objective of projects and programmes then the needs identified by communities must be recognised and attitude of sharing power encouraged.
Collapse
Affiliation(s)
| | - Alain Mpanya
- Coordination, Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of Congo
| | - Epco Hasker
- Public Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Erick Miaka
- Coordination, Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of Congo
| | - Ruth Nzuzi
- Coordination, Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of Congo
| | - Justin Pulford
- International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Steve Torr
- Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Dennis Perez Chacon
- Epidemiology, Pedro Kouri Institute of Tropical Medicine Center for Diagnostic and Reference Research, La Habana, Cuba
| |
Collapse
|
3
|
Kande Betu Kumesu V, Mutombo Kalonji W, Bardonneau C, Valverde Mordt O, Ngolo Tete D, Blesson S, Simon F, Delhomme S, Bernhard S, Nganzobo Ngima P, Mahenzi Mbembo H, Fina Lubaki JP, Lumeya Vuvu S, Kuziena Mindele W, Ilunga Wa Kyhi M, Mandula Mokenge G, Kaninda Badibabi L, Kasongo Bonama A, Kavunga Lukula P, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial. THE LANCET GLOBAL HEALTH 2022; 10:e1665-e1674. [PMID: 36179736 PMCID: PMC9554014 DOI: 10.1016/s2214-109x(22)00338-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 06/22/2022] [Accepted: 07/28/2022] [Indexed: 11/24/2022] Open
Abstract
Background Fexinidazole has been reported as an effective oral monotherapy against non-severe gambiense human African trypanosomiasis in a recent trial in adults. We aimed to assess the safety and efficacy of fexinidazole in children across all disease stages of gambiense human African trypanosomiasis. Methods We did a multicentre, single-arm, open-label, phase 2–3 trial at eight district hospitals in the Democratic Republic of the Congo. We recruited children with a Karnofsky score of more than 50, those aged 6 years to younger than 15 years, weighing 20 kg or more, and with confirmed gambiense human African trypanosomiasis (any stage). Children weighing 20 kg or more and less than 35 kg received oral fexinidazole of 1200 mg (two × 600 mg tablets) once per day for 4 days (days 1–4) followed by 600 mg (one × 600 mg tablet) once per day for 6 days (days 5–10). Children weighing 35 kg or more received oral fexinidazole of 1800 mg (three × 600 mg tablets) once per day for 4 days (days 1–4), followed by 1200 mg (two × 600 mg tablets) once per day for 6 days (days 5–10). The primary endpoint was fexinidazole treatment success rate 12 months after end of treatment. A rate greater than 80% was deemed acceptable and a target value of 92% was aimed for. Safety was assessed through routine monitoring. This study is completed and registered with ClinicalTrials.gov, number NCT02184689. Findings Between May 3, 2014, and Nov 22, 2016, we screened a total of 130 paediatric patients, of whom 125 (96%) received at least one dose of fexinidazole. All 125 patients (69 [55%] patients with stage 1, 19 [15%] with early stage 2, and 37 [30%] with late stage 2 gambiense human African trypanosomiasis) completed the 10-day treatment. Treatment success rate at 12 months was 97·6% (95% CI 93·1–99·5; 122 of 125 patients). The primary endpoint was met and the targeted value of 92% was exceeded. Treatment success at 12 months was elevated across all disease stages: 98·6% (95% CI 92·2–99·9; 68 of 69 patients) in stage 1, 94·7% (74·0–99·9; 18 of 19 patients) in early stage 2, and 97·3% (85·8–99·9; 36 of 37 patients) in late stage 2 gambiense human African trypanosomiasis. No new safety issues were observed beyond those found in adult trials. Overall, 116 (93%) of 125 patients reported 586 treatment-emergent adverse events, mainly mild or moderate. The most frequently reported treatment-emergent adverse events of interest during hospital admission were vomiting (86 [69%] of 125) and headache (41 [33%]). Seven (6%) of 125 patients had severe malaria, which was often accompanied by anaemia that was unrelated to fexinidazole. One patient died following dyspnoea and injury due to traumatic aggression 172 days after end of treatment, which was considered unrelated to fexinidazole or gambiense human African trypanosomiasis. Interpretation Oral fexinidazole is a safe and effective first-line treatment option across all gambiense human African trypanosomiasis disease stages in paediatric patients. Funding Through the Drugs for Neglected Diseases initiative: the Bill & Melinda Gates Foundation (USA), the Republic and Canton of Geneva (Switzerland), the Dutch Ministry of Foreign Affairs (Netherlands), the Norwegian Agency for Development Cooperation (Norway), the Federal Ministry of Education and Research through KfW (Germany), the Brian Mercer Charitable Trust (UK), and other private foundations and individuals from the human African trypanosomiasis campaign. Translation For the French translation of the abstract see Supplementary Materials section.
Collapse
|
4
|
Kayembe HCN, Linard C, Bompangue D, Muwonga J, Moutschen M, Situakibanza H, Ozer P. The spread of cholera in western Democratic Republic of the Congo is not unidirectional from East-West: a spatiotemporal analysis, 1973-2018. BMC Infect Dis 2021; 21:1261. [PMID: 34923959 PMCID: PMC8684622 DOI: 10.1186/s12879-021-06986-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Accepted: 12/16/2021] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Cholera outbreaks in western Democratic Republic of the Congo (DRC) are thought to be primarily the result of westward spread of cases from the Great Lakes Region. However, other patterns of spatial spread in this part of the country should not be excluded. The aim of this study was to explore alternative routes of spatial spread in western DRC. METHODS A literature review was conducted to reconstruct major outbreak expansions of cholera in western DRC since its introduction in 1973. We also collected data on cholera cases reported at the health zone (HZ) scale by the national surveillance system during 2000-2018. Based on data from routine disease surveillance, we identified two subperiods (week 45, 2012-week 42, 2013 and week 40, 2017-week 52, 2018) for which the retrospective space-time permutation scan statistic was implemented to detect spatiotemporal clusters of cholera cases and then to infer the spread patterns in western DRC other than that described in the literature. RESULTS Beyond westward and cross-border spread in the West Congo Basin from the Great Lakes Region, other dynamics of cholera epidemic propagation were observed from neighboring countries, such as Angola, to non-endemic provinces of southwestern DRC. Space-time clustering analyses sequentially detected clusters of cholera cases from southwestern DRC to the northern provinces, demonstrating a downstream-to-upstream spread along the Congo River. CONCLUSIONS The spread of cholera in western DRC is not one-sided. There are other patterns of spatial spread, including a propagation from downstream to upstream areas along the Congo River, to be considered as preferential trajectories of cholera in western DRC.
Collapse
Affiliation(s)
- Harry César Ntumba Kayembe
- Service d'Ecologie et Contrôle des Maladies Infectieuses, Département des Sciences de Base, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.
- Département de Sciences Et Gestion de L'environnement, Faculté Des Sciences, Université de Liège, Arlon, Belgium.
- Service d'Ecologie et Contrôle des Maladies Infectieuses, Département des Sciences de Base, Faculté de Médecine, Université de Kinshasa, Kin XI, B.P. : 834, Kinshasa, Democratic Republic of the Congo.
| | | | - Didier Bompangue
- Service d'Ecologie et Contrôle des Maladies Infectieuses, Département des Sciences de Base, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
- Chrono-Environnement, UMR CNRS 6249, Université de Franche-Comté, Besançon, France
| | - Jérémie Muwonga
- Département de Biologie Clinique, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Michel Moutschen
- Département des Sciences Cliniques, Immunopathologie-Maladies infectieuses et Médecine interne générale, Université de Liège, Liege, Belgium
| | - Hippolyte Situakibanza
- Département de Médecine Interne, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
- Département de Parasitologie Et Médecine Tropicale, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Pierre Ozer
- Département de Sciences Et Gestion de L'environnement, Faculté Des Sciences, Université de Liège, Arlon, Belgium
| |
Collapse
|
5
|
Kuemmerle A, Schmid C, Bernhard S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Tete DN, Kisala M, Burri C, Blesson S, Valverde Mordt O. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study. PLoS Negl Trop Dis 2021; 15:e0009903. [PMID: 34748572 PMCID: PMC8601604 DOI: 10.1371/journal.pntd.0009903] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 11/18/2021] [Accepted: 10/12/2021] [Indexed: 11/19/2022] Open
Abstract
Background Nifurtimox-eflornithine combination therapy (NECT) for the treatment of second stage gambiense human African trypanosomiasis (HAT) was added to the World Health Organization’s Essential Medicines List in 2009 after demonstration of its non-inferior efficacy compared to eflornithine therapy. A study of NECT use in the field showed acceptable safety and high efficacy until hospital discharge in a wide population, including children, pregnant and breastfeeding women, and patients with a HAT treatment history. We present here the effectiveness results after the 24-month follow-up visit. Methodology/Principal findings In a multicenter, open label, single arm phase IIIb study, second stage gambiense HAT patients were treated with NECT in the Democratic Republic of Congo. Clinical cure was defined 24 months after treatment as survival without clinical and/or parasitological signs of HAT. Of the 629 included patients, 619 (98.4%) were discharged alive after treatment and were examined for the presence of trypanosomes, white blood cell count in cerebro-spinal fluid, and disease symptoms. The clinical cure rate of 94.1% was comparable for all subpopulations analyzed at the 24-month follow-up visit. Self-reported adverse events during follow-up were few and concerned mainly nervous system disorders, infections, and gastro-intestinal disorders. Overall, 28 patients (4.3%) died during the course of the trial. The death of 16 of the 18 patients who died during the follow-up period was assessed as unlikely or not related to NECT. Within 24 months, eight patients (1.3%) relapsed and received rescue treatment. Sixteen patients were completely lost to follow-up. Conclusions/Significance NECT treatment administered under field conditions was effective and sufficiently well tolerated, no major concern arose for children or pregnant or breastfeeding women. Patients with a previous HAT treatment history had the same response as those who were naïve. In conclusion, NECT was confirmed as effective and appropriate for use in a broad population, including vulnerable subpopulations. Trial registration The trial is registered at ClinicalTrials.gov, number NCT00906880. The advanced stage of the neglected tropical disease human African trypanosomiasis was, until relatively recently, treated with an old toxic arsenical drug and there was little investment in an improved treatment option. Eflornithine alone was efficacious, but difficult to administer as it required four two-hour infusions a day for 14 days. Nifurtimox-eflornithine combination therapy (NECT) was developed as a simplified and easier to use treatment and was shown to be effective and sufficiently well tolerated in a randomized clinical trial. The present study was conducted to assess the overall effectiveness, including the feasibility of implementation of NECT under field conditions in a wider population than in the randomized clinical trial. We found that NECT can be implemented under field conditions and in remote areas, with the necessary logistical support and staff training for treatment administration. Adverse events, although very frequent, were considered acceptable given the severity of the disease. Less than 10% of patients showed severe adverse events. Over 24 months, the case fatality rate was 4.5% and relapses were rare (1.3%). The effectiveness of NECT was confirmed in a broad spectrum of second stage gambiense HAT patients, including children, pregnant and breastfeeding women, and patients who had been previously treated for HAT.
Collapse
Affiliation(s)
- Andrea Kuemmerle
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Caecilia Schmid
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Sonja Bernhard
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | - Victor Kande
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of the Congo
| | - Wilfried Mutombo
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of the Congo
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| | - Medard Ilunga
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of the Congo
| | - Ismael Lumpungu
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of the Congo
| | - Sylvain Mutanda
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of the Congo
| | - Pathou Nganzobo
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of the Congo
| | - Digas Ngolo Tete
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of the Congo
- Drugs for Neglected Diseases initiative, Geneva, Switzerland
| | - Mays Kisala
- Bureau Diocesain d’Oeuvres Médicales (BDOM), Kikwit, Democratic Republic of the Congo
| | - Christian Burri
- Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| | | | | |
Collapse
|
6
|
Snijders R, Fukinsia A, Claeys Y, Hasker E, Mpanya A, Miaka E, Meheus F, Boelaert M. Costs and Outcomes of Integrated Human African Trypanosomiasis Surveillance System Using Rapid Diagnostic Tests, Democratic Republic of the Congo. Emerg Infect Dis 2021; 27:2144-2153. [PMID: 34287133 PMCID: PMC8314840 DOI: 10.3201/eid2708.202399] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We integrated sleeping sickness case detection into the primary healthcare system in 2 health districts in the Democratic Republic of the Congo. We replaced a less field-friendly serologic test with a rapid diagnostic test, which was followed up by human African trypanosomiasis microscopic testing, and used a mixed costing methodology to estimate costs from a healthcare provider perspective. We screened a total of 18,225 persons and identified 27 new cases. Average financial cost (i.e., actual expenditures) was US $6.70/person screened and $4,464/case diagnosed and treated. Average economic cost (i.e., value of resources foregone that could have been used for other purposes) was $9.40/person screened and $6,138/case diagnosed and treated. Our study shows that integrating sleeping sickness surveillance into the primary healthcare system is feasible and highlights challenges in completing the diagnostic referral process and developing a context-adapted diagnostic algorithm for the large-scale implementation of this strategy in a sustainable and low-cost manner.
Collapse
|
7
|
Feasibility of a dried blood spot strategy for serological screening and surveillance to monitor elimination of Human African Trypanosomiasis in the Democratic Republic of the Congo. PLoS Negl Trop Dis 2021; 15:e0009407. [PMID: 34115754 PMCID: PMC8195376 DOI: 10.1371/journal.pntd.0009407] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 04/25/2021] [Indexed: 11/19/2022] Open
Abstract
In recent years, the number of reported Human African Trypanosomiasis (HAT) cases caused by Trypanosoma brucei (T.b.) gambiense has been markedly declining, and the goal of ‘elimination as a public health problem’ is within reach. For the next stage, i.e. interruption of HAT transmission by 2030, intensive screening and surveillance will need to be maintained, but with tools and strategies more efficiently tailored to the very low prevalence. We assessed the sequential use of ELISA and Immune Trypanolysis (ITL) on dried blood spot (DBS) samples as an alternative to the traditional HAT field testing and confirmation approach. A cross-sectional study was conducted in HAT endemic and previously endemic zones in Kongo Central province, and a non-endemic zone in Haut Katanga province in the Democratic Republic of the Congo (DRC). Door-to-door visits were performed to collect dried blood spot (DBS) samples on filter paper. ELISA/T.b. gambiense was conducted followed by ITL for those testing positive by ELISA and in a subset of ELISA negatives. In total, 11,642 participants were enrolled. Of these, 11,535 DBS were collected and stored in appropriate condition for ELISA testing. Ninety-seven DBS samples tested positive on ELISA. In the endemic zone, ELISA positivity was 1.34% (95%CI: 1.04–1.64). In the previously endemic zone and non-endemic zone, ELISA positivity was 0.34% (95% CI: 0.13–0.55) and 0.37% (95% CI: 0.15–0.60) respectively. Among the ELISA positives, only two samples had a positive ITL result, both from the endemic zone. One of those was from a former HAT patient treated in 2008 and the other from an individual who unfortunately had deceased prior to the follow-up visit. Our study showed that a surveillance strategy, based on DBS samples and centralized testing with retracing of patients if needed, is feasible in DRC. ELISA seems well suited as initial test with a similar positivity rate as traditional screening tests, but ITL remains complex. Alternatives for the latter, also analyzable on DBS, should be further explored. Human African Trypanosomiasis (HAT), also known as sleeping sickness is a parasitic disease, transmitted by tsetse flies, that is usually fatal if untreated. The number of cases have been rapidly declining over the past years indicating that elimination of the disease as a public health problem is within reach. To achieve the next stage, i.e. interruption of HAT transmission by 2030, intensive screening and surveillance will need to be maintained, but with tools and strategies more efficiently tailored to the very low prevalence. In contrast to the traditional approach of sending laboratory expertise to the field, we assessed an alternative approach based on the collection of dried blood samples on filter paper that were tested in a regional laboratory. Samples were taken in endemic, previously endemic and non-endemic villages and tested by ELISA and Immune Trypanolysis. The ELISA positivity rates were similar to those of other screening techniques currently used and Immune Trypanolysis was highly specific. Hence for surveillance in HAT endemic areas, collecting dried blood samples followed by centralized testing could become an alternative to the current strategy of active screening by mobile teams with on the spot confirmation. It has also potential for post-elimination surveillance to monitor resurgence and for exploratory surveillance in historic foci. Though highly specific, Immune Trypanolysis remains too complex for use in intermediate level laboratories, to further expand this strategy an alternative second step test is required.
Collapse
|
8
|
Davis CN, Rock KS, Antillón M, Miaka EM, Keeling MJ. Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo. BMC Med 2021; 19:86. [PMID: 33794881 PMCID: PMC8017623 DOI: 10.1186/s12916-021-01943-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 02/16/2021] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Gambiense human African trypanosomiasis (gHAT) has been brought under control recently with village-based active screening playing a major role in case reduction. In the approach to elimination, we investigate how to optimise active screening in villages in the Democratic Republic of Congo, such that the expenses of screening programmes can be efficiently allocated whilst continuing to avert morbidity and mortality. METHODS We implement a cost-effectiveness analysis using a stochastic gHAT infection model for a range of active screening strategies and, in conjunction with a cost model, we calculate the net monetary benefit (NMB) of each strategy. We focus on the high-endemicity health zone of Kwamouth in the Democratic Republic of Congo. RESULTS High-coverage active screening strategies, occurring approximately annually, attain the highest NMB. For realistic screening at 55% coverage, annual screening is cost-effective at very low willingness-to-pay thresholds (20.4 per disability adjusted life year (DALY) averted), only marginally higher than biennial screening (14.6 per DALY averted). We find that, for strategies stopping after 1, 2 or 3 years of zero case reporting, the expected cost-benefits are very similar. CONCLUSIONS We highlight the current recommended strategy-annual screening with three years of zero case reporting before stopping active screening-is likely cost-effective, in addition to providing valuable information on whether transmission has been interrupted.
Collapse
Affiliation(s)
- Christopher N Davis
- Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK.
- Zeeman Institute (SBIDER), University of Warwick, Coventry, CV4 7AL, UK.
| | - Kat S Rock
- Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
- Zeeman Institute (SBIDER), University of Warwick, Coventry, CV4 7AL, UK
| | - Marina Antillón
- Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel, 4051, Switzerland
- University of Basel, Petersplatz 1, Basel, 4051, Switzerland
| | - Erick Mwamba Miaka
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Ave Coisement Liberation et Bd Triomphal No 1, Commune de Kasavubu, Kinshasa, Democratic Republic of Congo
| | - Matt J Keeling
- Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
- Zeeman Institute (SBIDER), University of Warwick, Coventry, CV4 7AL, UK
- School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK
| |
Collapse
|
9
|
Crump RE, Huang CI, Knock ES, Spencer SEF, Brown PE, Mwamba Miaka E, Shampa C, Keeling MJ, Rock KS. Quantifying epidemiological drivers of gambiense human African Trypanosomiasis across the Democratic Republic of Congo. PLoS Comput Biol 2021; 17:e1008532. [PMID: 33513134 PMCID: PMC7899378 DOI: 10.1371/journal.pcbi.1008532] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Revised: 02/22/2021] [Accepted: 11/12/2020] [Indexed: 11/18/2022] Open
Abstract
Gambiense human African trypanosomiasis (gHAT) is a virulent disease declining in burden but still endemic in West and Central Africa. Although it is targeted for elimination of transmission by 2030, there remain numerous questions about the drivers of infection and how these vary geographically. In this study we focus on the Democratic Republic of Congo (DRC), which accounted for 84% of the global case burden in 2016, to explore changes in transmission across the country and elucidate factors which may have contributed to the persistence of disease or success of interventions in different regions. We present a Bayesian fitting methodology, applied to 168 endemic health zones (∼100,000 population size), which allows for calibration of a mechanistic gHAT model to case data (from the World Health Organization HAT Atlas) in an adaptive and automated framework. It was found that the model needed to capture improvements in passive detection to match observed trends in the data within former Bandundu and Bas Congo provinces indicating these regions have substantially reduced time to detection. Health zones in these provinces generally had longer burn-in periods during fitting due to additional model parameters. Posterior probability distributions were found for a range of fitted parameters in each health zone; these included the basic reproduction number estimates for pre-1998 (R0) which was inferred to be between 1 and 1.14, in line with previous gHAT estimates, with higher median values typically in health zones with more case reporting in the 2000s. Previously, it was not clear whether a fall in active case finding in the period contributed to the declining case numbers. The modelling here accounts for variable screening and suggests that underlying transmission has also reduced greatly-on average 96% in former Equateur, 93% in former Bas Congo and 89% in former Bandundu-Equateur and Bandundu having had the highest case burdens in 2000. This analysis also sets out a framework to enable future predictions for the country.
Collapse
Affiliation(s)
- Ronald E. Crump
- Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom
- Mathematics Institute, The University of Warwick, Coventry, United Kingdom
- The School of Life Sciences, The University of Warwick, Coventry, United Kingdom
- * E-mail:
| | - Ching-I Huang
- Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom
- Mathematics Institute, The University of Warwick, Coventry, United Kingdom
| | - Edward S. Knock
- Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom
- The Department of Statistics, The University of Warwick, Coventry, United Kingdom
| | - Simon E. F. Spencer
- Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom
- The Department of Statistics, The University of Warwick, Coventry, United Kingdom
| | - Paul E. Brown
- Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom
- Mathematics Institute, The University of Warwick, Coventry, United Kingdom
| | - Erick Mwamba Miaka
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, D.R.C.
| | - Chansy Shampa
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, D.R.C.
| | - Matt J. Keeling
- Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom
- Mathematics Institute, The University of Warwick, Coventry, United Kingdom
- The School of Life Sciences, The University of Warwick, Coventry, United Kingdom
| | - Kat S. Rock
- Zeeman Institute for System Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, United Kingdom
- Mathematics Institute, The University of Warwick, Coventry, United Kingdom
| |
Collapse
|
10
|
Kwedi Nolna S, Ntonè R, Fouda Mbarga N, Mbainda S, Mutangala W, Boua B, Niba M, Okoko A. Integration of Traditional Healers in Human African Trypanosomiasis Case Finding in Central Africa: A Quasi-Experimental Study. Trop Med Infect Dis 2020; 5:E172. [PMID: 33212918 PMCID: PMC7709689 DOI: 10.3390/tropicalmed5040172] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 11/04/2020] [Accepted: 11/06/2020] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Based on the premise that Africans in rural areas seek health care from traditional healers, this study investigated a collaborative model between traditional healers and the national Human African Trypanosomiasis (HAT) programs across seven endemic foci in seven central African countries by measuring the model's contribution to HAT case finding. METHOD Traditional healers were recruited and trained by health professionals to identify HAT suspects based on its basics signs and symptoms and to refer them to the National Sleeping Sickness Control Program (NSSCP) for testing and confirmatory diagnosis. RESULTS 35 traditional healers were recruited and trained, 28 finally participated in this study (80%) and referred 278 HAT suspects, of which 20 (7.19%) were CATT positive for the disease. Most cases originated from Bandundu (45%) in the Democratic Republic of Congo and from Ngabe (35%) in Congo. Twelve (4.32%) patients had confirmatory diagnosis. Although a statistically significant difference was not shown in terms of case finding (p = 0.56), traditional healers were able to refer confirmed HAT cases that were ultimately cared for by NCSSPs. CONCLUSION Integrating traditional healers in the control program of HAT will likely enhance the detection of cases, thereby, eventually contributing to the elimination of HAT in the most affected communities.
Collapse
Affiliation(s)
- Sylvie Kwedi Nolna
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
- Capacity for Leadership Excellence and Research (CLEAR), Yaoundé, Cameroon;
| | - Rodrigue Ntonè
- Epicentre, Medecins Sans Frontières, Yaoundé, Cameroon; (R.N.); (N.F.M.)
| | | | | | - Willy Mutangala
- Ministry of Health, National HAT Program, Kinshasa, Democratic Republic of Congo;
| | - Bernard Boua
- Ministry of Health, National HAT Program, Bangui, Central African Republic;
| | - Miriam Niba
- Capacity for Leadership Excellence and Research (CLEAR), Yaoundé, Cameroon;
| | - Aline Okoko
- Organisation de Coordination pour la lutte contre les Endemies en Afrique Centrale (OCEAC), Yaoundé, Cameroon;
| |
Collapse
|
11
|
Lumbala C, Kayembe S, Makabuza J, Lutumba P, Van Geertruyden JP, Bessell PR, Ndung’u JM. Development and implementation of a strategy for intensified screening for gambiense human African trypanosomiasis in Kongo Central province, DRC. PLoS Negl Trop Dis 2020; 14:e0008779. [PMID: 33057341 PMCID: PMC7591064 DOI: 10.1371/journal.pntd.0008779] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 10/27/2020] [Accepted: 09/06/2020] [Indexed: 11/21/2022] Open
Abstract
Background The Democratic Republic of the Congo (DRC) accounts for the majority of the reported gambiense human African trypanosomiasis (HAT) cases. Kongo Central province in the DRC reports a relatively low, yet steady number of cases, and forms a transboundary focus with Angola and the Republic of Congo. This paper describes an intervention aimed at reducing the case burden in Kongo Central by improving passive case detection, complemented with reactive screening. Methodology/Principal findings At the initiation of this programme in August 2015, 620 health facilities were identified and equipped with Rapid Diagnostic Tests (RDTs) for HAT screening. Of these, 603 (97%) reported use of RDTs, and 584 (94%) that continued to use RDTs to the last quarter of 2016 were used in the analysis going forward. Among all health facilities involved, 23 were equipped to confirm HAT by microscopy, and 4 of the latter were equipped to perform molecular testing with loop-mediated isothermal amplification (LAMP). Patients clinically suspected of HAT were tested with an RDT and those with a positive RDT result were referred to the nearest microscopy facility for confirmatory testing. If RDT positive patients were negative by microscopy, they were tested by LAMP, either on fresh blood or blood that was dried on filter paper and transported to a facility performing LAMP. This network of diagnostic facilities reduced the median distance for a patient to travel to a screening facility from 13.7km when the classical card agglutination test for trypanosomiasis (CATT) was used as a screening test in the past, to 3.4km. As a consequence, passive case detection was improved by between 30% and 130% compared to the period before. Furthermore, the proportion of HAT cases detected in early stage disease by passive screening increased from 27% to 64%. Reactive screening took place in 20 villages where cases were reported by passive screening, and in 45 villages in the neighbourhood of these villages. Reactive screening was responsible for detection of 40% of cases, of which, 90% were in first stage of the disease. Conclusions This programme has demonstrated that it is possible to deploy passive screening for HAT at sub-country or country levels in the DRC, and this is made more effective when supplemented with reactive screening. Results and achievements showed an increase in the number of HAT cases detected, the majority of them in early disease, demonstrating that this strategy enables better population coverage and early detection of cases, which is critical in removing the HAT reservoir and interrupting transmission, and could contribute to HAT elimination in regions where it is implemented. A number of diagnostic tests for HAT have recently been developed, to improve case detection. We report on the use of these technologies in a strategy to increase coverage and early detection of HAT cases in Kongo Central province of DRC. All 620 health facilities in the focus were equipped with RDTs to test patients presenting with symptoms suggestive of HAT. Among these health facilities, 23 were upgraded to perform confirmatory testing, for a final diagnosis. This strategy has reduced the distance a patient travels to a facility screening for HAT, from 13.7km to 3.4km. From August 2015 to December 2016, the proportion of HAT cases detected, adjusted annually, increased by between 30% and 130% compared to the previous two years, and 64% of them were in early stage disease, compared to 27% previously. This strategy has enabled better population coverage, and when supplemented with reactive screening, the identification of local outbreaks and early detection of most cases, which is critical in removing the HAT reservoir and interrupting transmission, thus contributing to elimination of the disease.
Collapse
Affiliation(s)
- Crispin Lumbala
- Directorate of Disease Control, Ministry of Public Health, Democratic Republic of the Congo
- Global Health Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- * E-mail:
| | - Simon Kayembe
- Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
| | - Jacquies Makabuza
- Programme National de Lutte Contre la Trypanosomiase Humaine Africaine, Kinshasa, République Démocratique du Congo
| | - Pascal Lutumba
- Kinshasa University, Kinshasa, Democratic Republic of the Congo
| | | | | | | |
Collapse
|
12
|
Njamnshi AK, Seke Etet PF, Ngarka L, Perrig S, Olivera GC, Nfor LN, Njamnshi WY, Acho A, Muyembe JJ, Bentivoglio M, Rottenberg M, Kennedy PGE. The Actigraphy Sleep Score: A New Biomarker for Diagnosis, Disease Staging, and Monitoring in Human African Trypanosomiasis. Am J Trop Med Hyg 2020; 103:2244-2252. [PMID: 33078699 DOI: 10.4269/ajtmh.20-0340] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Human African trypanosomiasis (HAT) remains a serious public health problem with diagnostic and treatment challenges in many African countries. The absence of a gold-standard biomarker has been a major difficulty for accurate disease staging and treatment follow-up. We therefore attempted to develop a simple, affordable, and noninvasive biomarker for HAT diagnosis and staging. Simultaneous actigraphy and polysomnography as well as cerebrospinal fluid (CSF) white blood cell (WBC) count, trypanosome presence, and C-X-C motif ligand (CXCL)-10 cytokine levels were performed in 20 HAT patients and nine healthy individuals (controls) using standard procedures. The International HIV Dementia Scale (IHDS) was scored in some patients as a surrogate for clinical assessment. From actigraphic parameters, we developed a novel sleep score and used it to determine correlations with other HAT markers, and compared their performance in differentiating between patients and controls and between HAT stages. The novel actigraphy sleep score (ASS) had the following ranges: 0-25 (healthy controls), 67-103 (HAT stage I), 111-126 (HAT intermediate), and 133-250 (HAT stage II). Compared with controls, stage I patients displayed a 7-fold increase in the ASS (P < 0.01), intermediate stage patients a 10-fold increase (P < 0.001), and HAT stage II patients an almost 20-fold increase (P < 0.001). CXCL-10 showed high interindividual differences. White blood cell counts were only marked in HAT stage II patients with a high interindividual variability. The International HIV Dementia Scale score negatively correlated with the ASS. We report the development and better performance of a new biomarker, ASS, for HAT diagnosis, disease staging, and monitoring that needs to be confirmed in large cohort studies.
Collapse
Affiliation(s)
- Alfred K Njamnshi
- Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland.,Neuroscience Lab, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.,Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon
| | - Paul F Seke Etet
- Department of Neurological Sciences (DSNNMM), University of Verona, Verona, Italy.,Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland
| | - Leonard Ngarka
- Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland.,Neuroscience Lab, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.,Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon
| | - Stephen Perrig
- Sleep Studies Laboratory, Geneva University Hospitals, Geneva, Switzerland.,Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland
| | - Gabriela C Olivera
- Deparment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
| | - Leonard N Nfor
- Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland.,Neuroscience Lab, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.,Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon
| | - Wepnyu Y Njamnshi
- Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon.,Neuroscience Lab, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.,Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland
| | - Alphonse Acho
- Neuroscience Lab, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I, Yaoundé, Cameroon.,Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon
| | - Jean-Jacques Muyembe
- Institut National de la Recherche Biomédicale, Kinshasa, Democratic Republic of Congo
| | - Marina Bentivoglio
- Department of Neurological Sciences (DSNNMM), University of Verona, Verona, Italy
| | - Martin Rottenberg
- Deparment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
| | - Peter G E Kennedy
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom
| |
Collapse
|
13
|
Insights from quantitative and mathematical modelling on the proposed 2030 goal for gambiense human African trypanosomiasis (gHAT). Gates Open Res 2020; 3:1553. [PMID: 32411945 PMCID: PMC7193711 DOI: 10.12688/gatesopenres.13070.2] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/06/2020] [Indexed: 11/20/2022] Open
Abstract
Gambiense human African trypanosomiasis (gHAT) is a parasitic, vector-borne neglected tropical disease that has historically affected populations across West and Central Africa and can result in death if untreated. Following from the success of recent intervention programmes against gHAT, the World Health Organization (WHO) has defined a 2030 goal of global elimination of transmission (EOT). The key proposed indicator to measure achievement of the goal is zero reported cases. Results of previous mathematical modelling and quantitative analyses are brought together to explore both the implications of the proposed indicator and the feasibility of achieving the WHO goal. Whilst the indicator of zero case reporting is clear and measurable, it is an imperfect proxy for EOT and could arise either before or after EOT is achieved. Lagging reporting of infection and imperfect diagnostic specificity could result in case reporting after EOT, whereas the converse could be true due to underreporting, lack of coverage, and cryptic human and animal reservoirs. At the village-scale, the WHO recommendation of continuing active screening until there are three years of zero cases yields a high probability of local EOT, but extrapolating this result to larger spatial scales is complex. Predictive modelling of gHAT has consistently found that EOT by 2030 is unlikely across key endemic regions if current medical-only strategies are not bolstered by improved coverage, reduced time to detection and/or complementary vector control. Unfortunately, projected costs for strategies expected to meet EOT are high in the short term and strategies that are cost-effective in reducing burden are unlikely to result in EOT by 2030. Future modelling work should aim to provide predictions while taking into account uncertainties in stochastic dynamics and infection reservoirs, as well as assessment of multiple spatial scales, reactive strategies, and measurable proxies of EOT.
Collapse
|
14
|
Mulenga P, Chenge F, Boelaert M, Mukalay A, Lutumba P, Lumbala C, Luboya O, Coppieters Y. Integration of Human African Trypanosomiasis Control Activities into Primary Healthcare Services: A Scoping Review. Am J Trop Med Hyg 2020; 101:1114-1125. [PMID: 31482788 PMCID: PMC6838596 DOI: 10.4269/ajtmh.19-0232] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Human African trypanosomiasis (HAT) also known as sleeping sickness is targeted for elimination as a public health problem by 2020 and elimination of infection by 2030. Although the number of reported cases is decreasing globally, integration of HAT control activities into primary healthcare services is endorsed to expand surveillance and control. However, this integration process faces several challenges in the field. This literature review analyzes what is known about integrated HAT control to guide the integration process in an era of HAT elimination. We carried out a scoping review by searching PubMed and Google Scholar data bases as well as gray literature documents resulting in 25 documents included for analysis. The main reasons in favor to integrate HAT control were related to coverage, cost, quality of service, or sustainability. There were three categories of factors influencing the integration process: 1) the clinical evolution of HAT, 2) the organization of health services, and 3) the diagnostic and therapeutic tools. There is a consensus that both active and passive approaches to HAT case detection and surveillance need to be combined, in a context-sensitive way. However, apart from some documentation about the constraints faced by local health services, there is little evidence on how this synergy is best achieved.
Collapse
Affiliation(s)
- Philippe Mulenga
- School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Faculty of Medicine and School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.,Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Faustin Chenge
- Centre de Connaissances en Santé en République Démocratique du Congo, Kinshasa, Democratic Republic of the Congo.,Faculty of Medicine and School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
| | - Marleen Boelaert
- Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Abdon Mukalay
- Faculty of Medicine and School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
| | - Pascal Lutumba
- Department of Tropical Medicine, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
| | - Crispin Lumbala
- National Program for the Control of Human African Trypanosomiasis, Kinshasa, Democratic Republic of the Congo
| | - Oscar Luboya
- Faculty of Medicine and School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
| | - Yves Coppieters
- School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium
| |
Collapse
|
15
|
Matovu E, Katiti D, Kitibwa A, Kazibwe A, Kato CD, Biéler S, Ndung'u JM. Optimisation of template preparation and laboratory evaluation of the Loopamp™ Trypanosoma brucei kit for detection of parasite DNA in blood. Exp Parasitol 2020; 211:107844. [PMID: 32119932 DOI: 10.1016/j.exppara.2020.107844] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 10/24/2019] [Accepted: 01/24/2020] [Indexed: 11/18/2022]
Abstract
The Loopamp™ Trypanosoma brucei Detection Kit is the latest addition of molecular techniques for amplification of parasite DNA in biological materials. We have evaluated the kit on a number of preparations of crude templates from the blood of experimentally infected rodents, to provide the best option that can be extrapolated to resource-poor healthcare settings where human African trypanosomiasis (HAT) is endemic. We used rodent blood spiked with T. b. brucei at various serial dilutions to test whole blood, that was concentrated by differential lysis of red blood cells (RBCs) followed by centrifugation, or buffy coat samples recovered from whole blood after centrifugation. We also tested crude templates produced after lysis of blood with sodium dodecyl sulphate (SDS) or Triton X, and storage for up to 28 days at room temperature after spotting on filter paper or glass slides. Concentration by RBC lysis provided the highest analytical sensitivity (0.04 trypanosomes/ml), closely followed by the much cheaper SDS at 0.1 trypanosomes/ml sensitivity. We also monitored the persistence of DNA in lysed blood dried onto filter papers by testing them weekly with the LAMP kit and by PCR for the 177bp repeats characteristic of the T. brucei subspecies. At a concentration of 100 trypanosomes/ml, signals indicating presence of parasite DNA could be detected up to week 10, while at 10 trypanosomes/ml detection of signals was limited to week 4. Thus, an ordinary filter paper provides a convenient medium for preservation of trypanosome DNA at ambient conditions for use with the LAMP kit in the short run. Lysis of samples with SDS enhanced sensitivity by facilitating parasite DNA availability. This opens the avenue to incorporate LAMP in routine algorithms for HAT diagnosis and surveillance, as well as for monitoring elimination programs.
Collapse
Affiliation(s)
- Enock Matovu
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, P. O. Box 7062, Kampala, Uganda.
| | - Dianah Katiti
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, P. O. Box 7062, Kampala, Uganda
| | - Annah Kitibwa
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, P. O. Box 7062, Kampala, Uganda
| | - AnneJ Kazibwe
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, P. O. Box 7062, Kampala, Uganda
| | - Charles Drago Kato
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, P. O. Box 7062, Kampala, Uganda
| | - Sylvain Biéler
- Foundation for Innovative New Diagnostics (FIND), Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland
| | - Joseph Mathu Ndung'u
- Foundation for Innovative New Diagnostics (FIND), Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland
| |
Collapse
|
16
|
Castaño MS, Ndeffo-Mbah ML, Rock KS, Palmer C, Knock E, Mwamba Miaka E, Ndung’u JM, Torr S, Verlé P, Spencer SEF, Galvani A, Bever C, Keeling MJ, Chitnis N. Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC). PLoS Negl Trop Dis 2020; 14:e0007976. [PMID: 31961872 PMCID: PMC6994134 DOI: 10.1371/journal.pntd.0007976] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2019] [Revised: 01/31/2020] [Accepted: 12/06/2019] [Indexed: 11/19/2022] Open
Abstract
Since the turn of the century, the global community has made great progress towards the elimination of gambiense human African trypanosomiasis (HAT). Elimination programs, primarily relying on screening and treatment campaigns, have also created a rich database of HAT epidemiology. Mathematical models calibrated with these data can help to fill remaining gaps in our understanding of HAT transmission dynamics, including key operational research questions such as whether integrating vector control with current intervention strategies is needed to achieve HAT elimination. Here we explore, via an ensemble of models and simulation studies, how including or not disease stage data, or using more updated data sets affect model predictions of future control strategies.
Collapse
Affiliation(s)
- María Soledad Castaño
- Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
- * E-mail:
| | - Martial L. Ndeffo-Mbah
- School of Public Health, Yale University, New Haven, Connecticut, United States of America
- College of Veterinary Medicine and Biosciences, Texas A&M University, College Station, Texas, United States of America
| | - Kat S. Rock
- Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom
- Mathematics Institute, University of Warwick, Coventry, United Kingdom
| | - Cody Palmer
- Institute of Disease Modeling, Seattle, Washington, United States of America
| | - Edward Knock
- Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom
- Department of Statistics, University of Warwick, Coventry, United Kingdom
| | - Erick Mwamba Miaka
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, the Democratic Republic of the Congo
| | | | - Steve Torr
- Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
| | - Paul Verlé
- Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Simon E. F. Spencer
- Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom
- Department of Statistics, University of Warwick, Coventry, United Kingdom
| | - Alison Galvani
- School of Public Health, Yale University, New Haven, Connecticut, United States of America
| | - Caitlin Bever
- Institute of Disease Modeling, Seattle, Washington, United States of America
| | - Matt J. Keeling
- Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, University of Warwick, Coventry, United Kingdom
- Mathematics Institute, University of Warwick, Coventry, United Kingdom
| | - Nakul Chitnis
- Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
- University of Basel, Basel, Switzerland
| |
Collapse
|
17
|
Falisse JB, Mwamba-Miaka E, Mpanya A. Whose Elimination? Frontline Workers' Perspectives on the Elimination of the Human African Trypanosomiasis and Its Anticipated Consequences. Trop Med Infect Dis 2020; 5:tropicalmed5010006. [PMID: 31906341 PMCID: PMC7157216 DOI: 10.3390/tropicalmed5010006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Revised: 12/20/2019] [Accepted: 12/25/2019] [Indexed: 01/06/2023] Open
Abstract
While academic literature has paid careful attention to the technological efforts―drugs, tests, and tools for vector control―deployed to eliminate Gambiense Human African Trypanosomiasis (HAT), the human resources and health systems dimensions of elimination are less documented. This paper analyses the perspectives and experiences of frontline nurses, technicians, and coordinators who work for the HAT programme in the former province of Bandundu in the Democratic Republic of the Congo, at the epidemic’s very heart. The research is based on 21 semi-structured interviews conducted with frontline workers in February 2018. The results highlight distinctive HAT careers as well as social elevation through specialised work. Frontline workers are concerned about changes in active screening strategies and the continued existence of the vector, which lead them to question the possibility of imminent elimination. Managers seem to anticipate a post-HAT situation and prepare for the employment of their staff; most workers see their future relatively confidently, as re-allocated to non-vertical units. The findings suggest concrete pathways for improving the effectiveness of elimination efforts: improving active screening through renewed engagements with local leaders, conceptualising horizontal integration in terms of human resources mobility, and investing more in detection and treatment activities (besides innovation).
Collapse
Affiliation(s)
- Jean-Benoît Falisse
- Centre of African Studies, University of Edinburgh, Edinburgh EH8 9LD, UK
- Correspondence: ; Tel.: +44-131-651-1632
| | - Erick Mwamba-Miaka
- Programme National de lutte contre la THA (PNLTHA), Kinshasa 2, Democratic Republic of the Congo; (E.M.-M.); (A.M.)
| | - Alain Mpanya
- Programme National de lutte contre la THA (PNLTHA), Kinshasa 2, Democratic Republic of the Congo; (E.M.-M.); (A.M.)
- Faculté des Sciences de la Santé, Université Pedagogique Nationale (UPN), Kinshasa BP 8815, Democratic Republic of the Congo
| |
Collapse
|
18
|
Ndeffo-Mbah ML, Pandey A, Atkins KE, Aksoy S, Galvani AP. The impact of vector migration on the effectiveness of strategies to control gambiense human African trypanosomiasis. PLoS Negl Trop Dis 2019; 13:e0007903. [PMID: 31805051 PMCID: PMC6894748 DOI: 10.1371/journal.pntd.0007903] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Accepted: 11/04/2019] [Indexed: 02/06/2023] Open
Abstract
Background Several modeling studies have been undertaken to assess the feasibility of the WHO goal of eliminating gambiense human African trypanosomiasis (g-HAT) by 2030. However, these studies have generally overlooked the effect of vector migration on disease transmission and control. Here, we evaluated the impact of vector migration on the feasibility of interrupting transmission in different g-HAT foci. Methods We developed a g-HAT transmission model of a single tsetse population cluster that accounts for migration of tsetse fly into this population. We used a model calibration approach to constrain g-HAT incidence to ranges expected for high, moderate and low transmission settings, respectively. We used the model to evaluate the effectiveness of current intervention measures, including medical intervention through enhanced screening and treatment, and vector control, for interrupting g-HAT transmission in disease foci under each transmission setting. Results We showed that, in low transmission settings, under enhanced medical intervention alone, at least 70% treatment coverage is needed to interrupt g-HAT transmission within 10 years. In moderate transmission settings, a combination of medical intervention and a vector control measure with a daily tsetse mortality greater than 0.03 is required to achieve interruption of disease transmission within 10 years. In high transmission settings, interruption of disease transmission within 10 years requires a combination of at least 70% medical intervention coverage and at least 0.05 tsetse daily mortality rate from vector control. However, the probability of achieving elimination in high transmission settings decreases with an increased tsetse migration rate. Conclusion Our results suggest that the WHO 2030 goal of G-HAT elimination is, at least in theory, achievable. But the presence of tsetse migration may reduce the probability of interrupting g-HAT transmission in moderate and high transmission foci. Therefore, optimal vector control programs should incorporate monitoring and controlling of vector density in buffer areas around foci of g-HAT control efforts. Gambian human African trypanosomiasis (g-HAT), also known as sleeping sickness, is a vector-borne parasitic disease transmitted by tsetse flies. If untreated, g-HAT infection will usually result in death. Recently, the World Health Organization (WHO) has targeted g-HAT for elimination through achieving interruption of transmission by 2030. To help inform elimination efforts, mathematical models have been used to evaluate the feasibility of the WHO goals in different g-HAT transmission foci. However, these mathematical models have generally ignored the role that tsetse migration may have in the spread and reemergence of g-HAT. Using a mathematical model, we evaluate the impact of tsetse migration on the effectiveness of current intervention measures for achieving interruption of g-HAT transmission in different transmission foci. We consider different interventions such as enhanced screening and treatment and vector control. We show that vector control has a great potential for reducing transmission. Still, the presence and intensity of tsetse migration can undermine its effectiveness for interrupting disease transmission, especially in high transmission foci. Our results indicate the need of accounting for tsetse surveillance and migration data in designing vector control efforts for g-HAT elimination.
Collapse
Affiliation(s)
- Martial L. Ndeffo-Mbah
- Department of Veterinary Integrative Biosciences, Texas A&M College of Veterinary Medicine and Biomedical Sciences, College Station, TX, United States of America
- Department of Epidemiology and Biostatistics, Texas A&M School of Public Health, College Station, TX, United States of America
- * E-mail:
| | - Abhishek Pandey
- Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, United States of America
- Department of Epidemiology and Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America
| | - Katherine E. Atkins
- Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
- Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
- Centre for Global Health, The Usher Institute for Population Health Sciences and Informatics, Edinburgh Medical School, The University of Edinburgh, Edinburgh, United Kingdom
| | - Serap Aksoy
- Department of Epidemiology and Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America
| | - Alison P. Galvani
- Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT, United States of America
- Department of Epidemiology and Microbial Diseases, Yale School of Public Health, New Haven, CT, United States of America
| |
Collapse
|
19
|
Rock KS, Ndeffo-Mbah ML, Castaño S, Palmer C, Pandey A, Atkins KE, Ndung'u JM, Hollingsworth TD, Galvani A, Bever C, Chitnis N, Keeling MJ. Assessing Strategies Against Gambiense Sleeping Sickness Through Mathematical Modeling. Clin Infect Dis 2019; 66:S286-S292. [PMID: 29860287 PMCID: PMC5982708 DOI: 10.1093/cid/ciy018] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Background Control of gambiense sleeping sickness relies predominantly on passive and active screening of people, followed by treatment. Methods Mathematical modeling explores the potential of 3 complementary interventions in high- and low-transmission settings. Results Intervention strategies that included vector control are predicted to halt transmission most quickly. Targeted active screening, with better and more focused coverage, and enhanced passive surveillance, with improved access to diagnosis and treatment, are both estimated to avert many new infections but, when used alone, are unlikely to halt transmission before 2030 in high-risk settings. Conclusions There was general model consensus in the ranking of the 3 complementary interventions studied, although with discrepancies between the quantitative predictions due to differing epidemiological assumptions within the models. While these predictions provide generic insights into improving control, the most effective strategy in any situation depends on the specific epidemiology in the region and the associated costs.
Collapse
Affiliation(s)
- Kat S Rock
- Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, Coventry, United Kingdom.,School of Life Sciences, University of Warwick, Coventry, United Kingdom
| | | | - Soledad Castaño
- Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Switzerland.,University of Basel, Switzerland
| | - Cody Palmer
- Institute of Disease Modeling, Bellevue, Washington
| | - Abhishek Pandey
- Yale School of Public Health, Yale University, New Haven, Connecticut
| | - Katherine E Atkins
- Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, United Kingdom.,Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, United Kingdom
| | | | - T Déirdre Hollingsworth
- Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, Coventry, United Kingdom.,School of Life Sciences, University of Warwick, Coventry, United Kingdom.,Mathematics Institute, University of Warwick, Coventry, United Kingdom
| | - Alison Galvani
- Yale School of Public Health, Yale University, New Haven, Connecticut
| | | | - Nakul Chitnis
- Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Switzerland.,University of Basel, Switzerland
| | - Matt J Keeling
- Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, Coventry, United Kingdom.,School of Life Sciences, University of Warwick, Coventry, United Kingdom.,Mathematics Institute, University of Warwick, Coventry, United Kingdom
| |
Collapse
|
20
|
Davis CN, Rock KS, Mwamba Miaka E, Keeling MJ. Village-scale persistence and elimination of gambiense human African trypanosomiasis. PLoS Negl Trop Dis 2019; 13:e0007838. [PMID: 31658269 PMCID: PMC6837580 DOI: 10.1371/journal.pntd.0007838] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 11/07/2019] [Accepted: 10/10/2019] [Indexed: 11/18/2022] Open
Abstract
Gambiense human African trypanosomiasis (gHAT) is one of several neglected tropical diseases that is targeted for elimination by the World Health Organization. Recent years have seen a substantial decline in the number of globally reported cases, largely driven by an intensive process of screening and treatment. However, this infection is highly focal, continuing to persist at low prevalence even in small populations. Regional elimination, and ultimately global eradication, rests on understanding the dynamics and persistence of this infection at the local population scale. Here we develop a stochastic model of gHAT dynamics, which is underpinned by screening and reporting data from one of the highest gHAT incidence regions, Kwilu Province, in the Democratic Republic of Congo. We use this model to explore the persistence of gHAT in villages of different population sizes and subject to different patterns of screening. Our models demonstrate that infection is expected to persist for long periods even in relatively small isolated populations. We further use the model to assess the risk of recrudescence following local elimination and consider how failing to detect cases during active screening events informs the probability of elimination. These quantitative results provide insights for public health policy in the region, particularly highlighting the difficulties in achieving and measuring the 2030 elimination goal.
Collapse
Affiliation(s)
- Christopher N. Davis
- MathSys CDT, Mathematics Institute, University of Warwick, Coventry, United Kingdom
- Zeeman Institute (SBIDER), University of Warwick, Coventry, United Kingdom
| | - Kat S. Rock
- Zeeman Institute (SBIDER), University of Warwick, Coventry, United Kingdom
- Mathematics Institute, University of Warwick, Coventry, United Kingdom
| | - Erick Mwamba Miaka
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Ave Coisement Liberation et Bd Triomphal No 1, Commune de Kasavubu, Kinshasa, Demecratic Republic of the Congo
| | - Matt J. Keeling
- Zeeman Institute (SBIDER), University of Warwick, Coventry, United Kingdom
- Mathematics Institute, University of Warwick, Coventry, United Kingdom
- School of Life Sciences, University of Warwick, Coventry, United Kingdom
- * E-mail:
| |
Collapse
|
21
|
Mulenga P, Lutumba P, Coppieters Y, Mpanya A, Mwamba-Miaka E, Luboya O, Chenge F. Passive Screening and Diagnosis of Sleeping Sickness with New Tools in Primary Health Services: An Operational Research. Infect Dis Ther 2019; 8:353-367. [PMID: 31309434 PMCID: PMC6702524 DOI: 10.1007/s40121-019-0253-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION The integration of human African trypanosomiasis (HAT) activities into primary health services is gaining importance as a result of the decreasing incidence of HAT and the ongoing developments of new screening and diagnostic tools. In the Democratic Republic of Congo, this integration process faces multiple challenges. We initiated an operational research project to document drivers and bottlenecks of the process. METHODS Three health districts piloted the integration of HAT screening and diagnosis into primary health services. We analysed the outcome indicators of this intervention and conducted in-depth interviews with health care providers, seropositives, community health workers and HD management team members. Our thematic interview guide focused on factors facilitating and impeding the integration of HAT screening. RESULTS The study showed a HAT-RDT-positive rate of 2.2% in Yasa Bonga, 2.9% in Kongolo and 3% in Bibanga, while the proportion of reported seropositives that received confirmatory examinations was 76%, 45.6% and 68%, respectively. Qualitative analyses indicated that some seropositives were unable to access the confirmation facility. The main reasons that were given included distance, RDT rupture, lack of basic screening equipment and financial barriers (additional hospital fees not included in free treatment course), fear of lumbar puncture and the perception of HAT as a disease of supernatural origin. CONCLUSION Passive screening using HAT RDTs in primary health services inevitably has some limitations. However, regarding the epidemiological context and some obstacles to integrated implementation, this cannot on its own be a relevant alternative to the elimination of HAT by 2020. FUNDING We acknowledge the agency that provided financial support for this study, the Belgian Development Cooperation. The funder had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. Philippe Mulenga received financial support thanks to a doctoral grant from the Belgian Development Cooperation under the FA4 agreement. Funding for the study and Rapid Service Fees was provided by the Epidemiology and Tropical Diseases Unit of the Institute of Tropical Medicine, Antwerp.
Collapse
Affiliation(s)
- Philippe Mulenga
- Faculty of Medicine & School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo.
- Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
- School of Public Health, Université Libre de Bruxelles, Brussels, Belgium.
| | - Pascal Lutumba
- Department of Tropical Medicine, University of Kinshasa, Faculty of Medicine, Kinshasa, Democratic Republic of the Congo
| | - Yves Coppieters
- School of Public Health, Université Libre de Bruxelles, Brussels, Belgium
| | - Alain Mpanya
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo
| | - Eric Mwamba-Miaka
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo
| | - Oscar Luboya
- Faculty of Medicine & School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
| | - Faustin Chenge
- Faculty of Medicine & School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of the Congo
- Centre de Connaissances en Santé en République Démocratique du Congo, Kinshasa, Democratic Republic of the Congo
| |
Collapse
|
22
|
Mulenga P, Boelaert M, Lutumba P, Vander Kelen C, Coppieters Y, Chenge F, Lumbala C, Luboya O, Mpanya A. Integration of Human African Trypanosomiasis Control Activities into Primary Health Services in the Democratic Republic of the Congo: A Qualitative Study of Stakeholder Perceptions. Am J Trop Med Hyg 2019; 100:899-906. [PMID: 30719963 PMCID: PMC6447127 DOI: 10.4269/ajtmh.18-0382] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Human African trypanosomiasis is close to elimination in several countries in sub-Saharan Africa. The diagnosis and treatment is currently rapidly being integrated into first-line health services. We aimed to document the perspective of stakeholders on this integration process. We conducted 12 focus groups with communities in three health zones of the Democratic Republic of the Congo and held 32 interviews with health-care providers, managers, policy makers, and public health experts. The topic guide focused on enabling and blocking factors related to the integrated diagnosis and treatment approach. The data were analyzed with NVivo (QSR International, Melbourne, Australia) using a thematic analysis process. The results showed that the community mostly welcomed integrated care for diagnosis and treatment of sleeping sickness, as they value the proximity of first-line health services, but feared possible financial barriers. Health-care professionals thought integration contributed to the elimination goal but identified several implementation challenges, such as the lack of skills, equipment, motivation and financial resources in these basic health services. Patients often use multiple therapeutic itineraries that do not necessarily lead them to health centers where screening is available. Financial barriers are important, as health care is not free in first-line health centers, in contrast to the population screening campaigns. Communities and providers signal several challenges regarding the integration process. To succeed, the required training of health professionals, as well as staff deployment and remuneration policy and the financial barriers in the primary care system need to be addressed, to ensure coverage for those most in need.
Collapse
Affiliation(s)
- Philippe Mulenga
- Faculty of Medicine and School of Public Health, University of Lubumbashi, Lubumbashi, DRC.,Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.,School of Public Health, Université Libre de Bruxelles, Brussels, Belgium
| | - Marleen Boelaert
- Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium
| | - Pascal Lutumba
- Department of Tropical Medicine, Faculty of Medicine, University of Kinshasa, Kinshasa, DRC
| | | | - Yves Coppieters
- School of Public Health, Université Libre de Bruxelles, Brussels, Belgium
| | - Faustin Chenge
- Faculty of Medicine and School of Public Health, University of Lubumbashi, Lubumbashi, DRC
| | - Crispin Lumbala
- National Program for the Control of Human African Trypanosomiasis, Kinshasa, DRC
| | - Oscar Luboya
- Faculty of Medicine and School of Public Health, University of Lubumbashi, Lubumbashi, DRC
| | - Alain Mpanya
- National Program for the Control of Human African Trypanosomiasis, Kinshasa, DRC
| |
Collapse
|
23
|
Franco JR, Cecchi G, Priotto G, Paone M, Diarra A, Grout L, Simarro PP, Zhao W, Argaw D. Monitoring the elimination of human African trypanosomiasis: Update to 2016. PLoS Negl Trop Dis 2018; 12:e0006890. [PMID: 30521525 PMCID: PMC6283345 DOI: 10.1371/journal.pntd.0006890] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Accepted: 10/01/2018] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Human African trypanosomiasis (HAT) is a neglected tropical disease targeted for elimination 'as a public health problem' by 2020. The indicators to monitor progress towards the target are based on the number of reported cases, the related areas and populations exposed at various levels of risk, and the coverage of surveillance activities. Based on data provided by the National Sleeping Sickness Control Programmes (NSSCP), Non-Governmental Organizations (NGOs) and research institutions-and assembled in the Atlas of HAT-the World Health Organization (WHO) provides here an update to 2016 for these indicators, as well as an analysis of the epidemiological situation. RESULTS Trends for the two primary indicators of elimination are on track for the 2020 goal: 2,164 cases of HAT were reported in 2016 (as compared to the milestone of 4,000 cases), and for the period 2012-2016 280,000 km2 are estimated to be at moderate risk or higher (i.e. ≥ 1 case/10,000 people/year), as compared to the milestone of 230,000 km2. These figures correspond to reductions of 92% and 61% as compared to the respective baselines (i.e. 26,550 HAT cases in the year 2000, and 709,000 km2 exposed at various levels of risk for the period 2000-2004). Among the secondary indicators, an overall improvement in the coverage of at risk populations by surveillance activities was observed. Regarding passive surveillance, the number of fixed health facilities providing gambiense HAT diagnosis or treatment expanded, with 1,338 enumerated in endemic countries in 2017 (+52% as compared to the survey completed only sixteen months earlier). Concerning rhodesiense HAT, 124 health facilities currently provide diagnosis or treatment. The broadening of passive surveillance is occurring in a context of fairly stable intensity of active case finding, with between 1.8 million and 2.4 million people screened per year over the period 2012-2016. DISCUSSION Elimination of HAT as a public health problem by 2020 seems within reach, as the epidemiological trends observed in previous years are confirmed in this latest 2016 monitoring update. However, looking beyond 2020, and in particular to the 2030 goal of elimination of transmission as zero cases for the gambiense form of the disease only, there is no room for complacency. Challenges still abound, including ensuring the effective integration of HAT control activities in the health system, sustaining the commitment of donors and HAT endemic countries, and clarifying the extent of the threat posed by cryptic reservoirs (e.g. human asymptomatic carriers and the possible animal reservoirs in gambiense HAT epidemiology). WHO provides through the network for HAT elimination the essential coordination of the wide range of stakeholders to ensure synergy of efforts.
Collapse
Affiliation(s)
- José R. Franco
- World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland
- * E-mail:
| | - Giuliano Cecchi
- Food and Agriculture Organization of the United Nations, Sub-regional Office for Eastern Africa, Addis Ababa, Ethiopia
| | - Gerardo Priotto
- World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland
| | - Massimo Paone
- Food and Agriculture Organization of the United Nations, Animal Production and Health Division, Rome, Italy
| | - Abdoulaye Diarra
- World Health Organization, Regional Office for Africa, Communicable Disease Unit, Brazzaville, Congo
| | - Lise Grout
- World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland
| | - Pere P. Simarro
- Consultant World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland
| | - Weining Zhao
- Food and Agriculture Organization of the United Nations, Animal Production and Health Division, Rome, Italy
| | - Daniel Argaw
- World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland
| |
Collapse
|
24
|
Rock KS, Pandey A, Ndeffo-Mbah ML, Atkins KE, Lumbala C, Galvani A, Keeling MJ. Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC. Epidemics 2018; 18:101-112. [PMID: 28279451 DOI: 10.1016/j.epidem.2017.01.006] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 01/31/2017] [Accepted: 01/31/2017] [Indexed: 02/04/2023] Open
Abstract
Approaching disease elimination, it is crucial to be able to assess progress towards key objectives using quantitative tools. For Gambian human African trypanosomiasis (HAT), the ultimate goal is to stop transmission by 2030, while intermediary targets include elimination as a public health problem - defined as <1 new case per 10,000 inhabitants in 90% of foci, and <2000 reported cases by 2020. Using two independent mathematical models, this study assessed the achievability of these goals in the former Equateur province of the Democratic Republic of Congo, which historically had endemic levels of disease. The two deterministic models used different assumptions on disease progression, risk of infection and non-participation in screening, reflecting biological uncertainty. To validate the models a censor-fit-uncensor procedure was used to fit to health-zone level data from 2000 to 2012; initially the last six years were censored, then three and the final step utilised all data. The different model projections were used to evaluate the expected transmission and reporting for each health zone within each province under six intervention strategies using currently available tools. In 2012 there were 197 reported HAT cases in former Equateur reduced from 6828 in 2000, however this reflects lower active testing for HAT (1.3% of the population compared to 7.2%). Modelling results indicate that there are likely to be <300 reported cases in former Equateur in 2020 if screening continues at the mean level for 2000-2012 (6.2%), and <120 cases if vector control is introduced. Some health zones may fail to achieve <1 new case per 10,000 by 2020 without vector control, although most appear on track for this target using medical interventions alone. The full elimination goal will be harder to reach; between 39 and 54% of health zones analysed may have to improve their current medical-only strategy to stop transmission completely by 2030.
Collapse
Affiliation(s)
- K S Rock
- Zeeman Institute: SBIDER (Systems Biology & Infectious Disease Epidemiology Research), University of Warwick, Coventry, CV4 7AL, UK; School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK.
| | - A Pandey
- Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, 06510, USA
| | - M L Ndeffo-Mbah
- Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, 06510, USA
| | - K E Atkins
- Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - C Lumbala
- Programme National de Lutte contre le Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, The Democratic Republic of Congo
| | - A Galvani
- Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, 06510, USA
| | - M J Keeling
- Zeeman Institute: SBIDER (Systems Biology & Infectious Disease Epidemiology Research), University of Warwick, Coventry, CV4 7AL, UK; School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK; Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
| |
Collapse
|
25
|
Zhang H, Collins J, Nyamwihura R, Ware S, Kaiser M, Ogungbe IV. Discovery of a quinoline-based phenyl sulfone derivative as an antitrypanosomal agent. Bioorg Med Chem Lett 2018; 28:1647-1651. [PMID: 29609908 PMCID: PMC5912169 DOI: 10.1016/j.bmcl.2018.03.039] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 03/06/2018] [Accepted: 03/15/2018] [Indexed: 11/28/2022]
Abstract
A series of natural products-based phenyl sulfone derivative and their property-based analogues were investigated as potential growth inhibitors of Trypanosoma brucei. Trypanosoma brucei is a kinetoplastid protozoan parasite that causes trypanosomiasis. In this work, we found that nopol- and quinoline-based phenyl sulfone derivative were the most active and selective for T. brucei, and they were not reactive towards the active thiol of T. brucei's cysteine protease rhodesain. A thiol reactive variant of the quinoline-based phenyl sulfone was subsequently investigated and found to be a moderate inhibitor of rhodesain. The quinoline-based compound that is not reactive towards rhodesain can serve a template for phenotypic-based lead discovery while its thiol-active congener can serve as template for structure-based investigation of new antitrypanosomal agents.
Collapse
Affiliation(s)
- Huaisheng Zhang
- Department of Chemistry, Jackson State University, Jackson, MS 39217, USA
| | - Jasmine Collins
- Department of Chemistry, Jackson State University, Jackson, MS 39217, USA
| | - Rogers Nyamwihura
- Department of Chemistry, Jackson State University, Jackson, MS 39217, USA
| | - Shelbi Ware
- Department of Chemistry, Jackson State University, Jackson, MS 39217, USA
| | - Marcel Kaiser
- Department of Medical Parasitology & Infection Biology, Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; University of Basel, Petersplatz 1, 4003 Basel, Switzerland
| | | |
Collapse
|
26
|
Bauerenol Acetate, the Pentacyclic Triterpenoid from Tabernaemontana longipes, is an Antitrypanosomal Agent. Molecules 2018; 23:molecules23020355. [PMID: 29419735 PMCID: PMC5911922 DOI: 10.3390/molecules23020355] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 02/02/2018] [Accepted: 02/06/2018] [Indexed: 01/11/2023] Open
Abstract
The Latin American plant Tabernaemontana longipes was studied in this work as a potential source of antiparasitic agents. The chloroform extract of T. longipes leaves was separated into several fractions, and tested for antitrypanosomal activity. One of the fractions displayed significant growth inhibitory activity against Trypanosoma brucei. The active principle in the fraction was isolated, purified, and characterized by NMR and mass spectrometry. The antitrypanosomal agent in the CHCl3 extract of T. longipes leaves is the pentacyclic triterpenoid bauerenol acetate. A metabolite profiling assay suggest that the triterpenoid influences cholesterol metabolism. The molecular target(s) of bauerenol and its acetate, like many other antiparasitic pentacyclic triterpenoids is/are unknown, but they present privileged structural scaffolds that can be explored for structure-based activity optimization studies using phenotypic assays.
Collapse
|
27
|
Kimuda MP, Noyes H, Mulindwa J, Enyaru J, Alibu VP, Sidibe I, Mumba Ngoyi D, Hertz-Fowler C, MacLeod A, Tastan Bishop Ö, Matovu E. No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations. PLoS Negl Trop Dis 2018; 12:e0006300. [PMID: 29470556 PMCID: PMC5844566 DOI: 10.1371/journal.pntd.0006300] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 03/09/2018] [Accepted: 02/05/2018] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Human African trypanosomiasis (HAT) manifests as an acute form caused by Trypanosoma brucei rhodesiense (Tbr) and a chronic form caused by Trypanosoma brucei gambiense (Tbg). Previous studies have suggested a host genetic role in infection outcomes, particularly for APOL1. We have undertaken candidate gene association studies (CGAS) in a Ugandan Tbr and a Tbg HAT endemic area, to determine whether polymorphisms in IL10, IL8, IL4, HLAG, TNFA, TNX4LB, IL6, IFNG, MIF, APOL1, HLAA, IL1B, IL4R, IL12B, IL12R, HP, HPR, and CFH have a role in HAT. METHODOLOGY AND RESULTS We included 238 and 202 participants from the Busoga Tbr and Northwest Uganda Tbg endemic areas respectively. Single Nucleotide Polymorphism (SNP) genotype data were analysed in the CGAS. The study was powered to find odds ratios > 2 but association testing of the SNPs with HAT yielded no positive associations i.e. none significant after correction for multiple testing. However there was strong evidence for no association with Tbr HAT and APOL1 G2 of the size previously reported in the Kabermaido district of Uganda. CONCLUSIONS/SIGNIFICANCE A recent study in the Soroti and Kaberamaido focus in Central Uganda found that the APOL1 G2 allele was strongly associated with protection against Tbr HAT (odds ratio = 0.2, 95% CI: 0.07 to 0.48, p = 0.0001). However, in our study no effect of G2 on Tbr HAT was found, despite being well powered to find a similar sized effect (OR = 0.9281, 95% CI: 0.482 to 1.788, p = 0.8035). It is possible that the G2 allele is protective from Tbr in the Soroti/Kabermaido focus but not in the Iganga district of Busoga, which differ in ethnicity and infection history. Mechanisms underlying HAT infection outcome and virulence are complex and might differ between populations, and likely involve several host, parasite or even environmental factors.
Collapse
Affiliation(s)
- Magambo Phillip Kimuda
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, Kampala, Uganda
- Research Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, Grahamstown, South Africa
| | - Harry Noyes
- Centre for Genomic Research, University of Liverpool, Liverpool, United Kingdom
| | - Julius Mulindwa
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, Kampala, Uganda
| | - John Enyaru
- College of Natural Sciences, Makerere University, Kampala, Uganda
| | | | - Issa Sidibe
- Unité Maladies à Vecteurs et Biodiversité, Centre International de Recherche-Développement sur l'Elevage en Zone Subhumide (CIRDES), Bobo-Dioulass, Burkina Faso
| | | | | | - Annette MacLeod
- Wellcome Center for Molecular Parasitology, University Place, Glasgow, United Kingdom
| | - Özlem Tastan Bishop
- Research Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, Grahamstown, South Africa
| | - Enock Matovu
- College of Veterinary Medicine, Animal Resources and Biosecurity (COVAB), Makerere University, Kampala, Uganda
| | | |
Collapse
|
28
|
Mesu VKBK, Kalonji WM, Bardonneau C, Mordt OV, Blesson S, Simon F, Delhomme S, Bernhard S, Kuziena W, Lubaki JPF, Vuvu SL, Ngima PN, Mbembo HM, Ilunga M, Bonama AK, Heradi JA, Solomo JLL, Mandula G, Badibabi LK, Dama FR, Lukula PK, Tete DN, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet 2018; 391:144-154. [PMID: 29113731 DOI: 10.1016/s0140-6736(17)32758-7] [Citation(s) in RCA: 161] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Revised: 10/12/2017] [Accepted: 10/13/2017] [Indexed: 10/18/2022]
Abstract
BACKGROUND Few therapeutic options are available to treat the late-stage of human African trypanosomiasis, a neglected tropical disease, caused by Trypanosoma brucei gambiense (g-HAT). The firstline treatment is a combination therapy of oral nifurtimox and intravenous eflornithine that needs to be administered in a hospital setting by trained personnel, which is not optimal given that patients often live in remote areas with few health resources. Therefore, we aimed to assess the safety and efficacy of an oral regimen of fexinidazole (a 2-substituted 5-nitroimidazole with proven trypanocidal activity) versus nifurtimox eflornithine combination therapy in patients with late-stage g-HAT. METHODS In this randomised, phase 2/3, open-label, non-inferiority trial, we recruited patients aged 15 years and older with late-stage g-HAT from g-HAT treatment centres in the Democratic Republic of the Congo (n=9) and the Central African Republic (n=1). Patients were randomly assigned (2:1) to receive either fexinidazole or nifurtimox eflornithine combination therapy according to a predefined randomisation list (block size six). The funder, data management personnel, and study statisticians were masked to treatment. Oral fexinidazole was given once a day (days 1-4: 1800 mg, days 5-10: 1200 mg). Oral nifurtimox was given three times a day (days 1-10: 15 mg/kg per day) with eflornithine twice a day as 2 h infusions (days 1-7: 400 mg/kg per day). The primary endpoint was success at 18 months (ie, deemed as patients being alive, having no evidence of trypanosomes in any body fluid, not requiring rescue medication, and having a cerebrospinal fluid white blood cell count ≤20 cells per μL). Safety was assessed through routine monitoring. Primary efficacy analysis was done in the modified intention-to-treat population and safety analyses in the intention-to-treat population. The acceptable margin for the difference in success rates was defined as 13%. This study has been completed and is registered with ClinicalTrials.gov, number NCT01685827. FINDINGS Between October, 2012, and November, 2016, 419 patients were pre-screened. Of the 409 eligible patients, 14 were not included because they did not meet all inclusion criteria (n=12) or for another reason (n=2). Therefore, 394 patients were randomly assigned, 264 to receive fexinidazole and 130 to receive nifurtimox eflornithine combination therapy. Success at 18 months was recorded in 239 (91%) patients given fexinidazole and 124 (98%) patients given nifurtimox eflornithine combination therapy, within the margin of acceptable difference of -6·4% (97·06% CI -11·2 to -1·6; p=0·0029). We noted no difference in the proportion of patients who experienced treatment-related adverse events (215 [81%] in the fexinidazole group vs 102 [79%] in the nifurtimox eflornithine combination therapy group). Treatment discontinuations were unrelated to treatment (n=2 [1%] in the fexinidazole group). Temporary nifurtimox eflornithine combination therapy interruption occurred in three (2%) patients. 11 patients died during the study (nine [3%] in the fexinidazole group vs two [2%] in the nifurtimox eflornithine combination therapy group). INTERPRETATION Our findings show that oral fexinidazole is effective and safe for the treatment of T b gambiense infection compared with nifurtimox eflornithine combination therapy in late-stage HAT patients. Fexinidazole could be a key asset in the elimination of this fatal neglected disease. FUNDING Drugs for Neglected Diseases initiative.
Collapse
Affiliation(s)
| | - Wilfried Mutombo Kalonji
- National HAT Control Programme (Programme National de Lutte contre la Trypanosomiase Humaine Africaine [PNLTHA]), Geneva, Switzerland
| | | | | | - Séverine Blesson
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | - François Simon
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | - Sophie Delhomme
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland
| | - Sonja Bernhard
- Swiss TPH, Basel, Switzerland; University of Basel, Basel, Petersplatz 1, PO Box, CH-4001 Basel, Switzerland
| | - Willy Kuziena
- Masi Manimba Hospital, Province Kwilu, Democratic Republic of the Congo
| | | | | | | | | | - Médard Ilunga
- Dipumba Hospital (MIBA), Mbuji Mayi, Province Kasaï Oriental, Democratic Republic of the Congo
| | | | | | | | - Guylain Mandula
- Mushie Hospital, Province Maï Ndombe, Democratic Republic of the Congo
| | | | | | | | - Digas Ngolo Tete
- Drugs for Neglected Diseases initiative (DNDi), Kinshasa, Democratic Republic of the Congo
| | - Crispin Lumbala
- Drugs for Neglected Diseases initiative (DNDi), Kinshasa, Democratic Republic of the Congo
| | - Bruno Scherrer
- Bruno Scherrer Conseil, Saint Arnoult en Yvelines, France
| | | | - Antoine Tarral
- Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland.
| |
Collapse
|
29
|
Boelaert M, Mukendi D, Bottieau E, Kalo Lilo JR, Verdonck K, Minikulu L, Barbé B, Gillet P, Yansouni CP, Chappuis F, Lutumba P. A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo. EBioMedicine 2017; 27:11-17. [PMID: 29246478 PMCID: PMC5828295 DOI: 10.1016/j.ebiom.2017.10.032] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 10/22/2017] [Accepted: 10/31/2017] [Indexed: 11/27/2022] Open
Abstract
Objectives To estimate the diagnostic accuracy of HAT Sero K-SeT for the field diagnosis of second-stage human African trypanosomiasis (HAT). Design A phase III diagnostic accuracy design. Consecutive patients with symptoms clinically suggestive of HAT were prospectively enrolled. We compared results of the index test HAT Sero K-SeT with those of a composite reference standard: demonstration of trypanosomes in cerebrospinal fluid (CSF), or trypanosomes detected in any other body fluid AND white blood cell count in CSF > 5/μl. Setting Rural hospital in the Democratic Republic of the Congo. Participants All patients above five years old presenting at Mosango hospital with a neurological problem of recent onset at the exclusion of trauma. Interventions n.a. Main Outcome Measures Sensitivity and specificity of HAT Sero K-SeT test. Results The sensitivity of the HAT Sero K-SeT was 8/8 or 100.0% (95% confidence interval: 67.6 to 100.0%) and the specificity was 258/266 or 97.0% (94.2% to 98.5%). Conclusion The high sensitivity of the HAT Sero K-SeT is in line with previously published estimates, though the sample of HAT cases in this study was small. The specificity estimate was very high and precise. This test, when negative, allows the clinician to rule out HAT in a clinical suspect in a hospital setting in this endemic region. The HAT Sero K-SeT was evaluated in a rural hospital on patients with a neurological syndrome. This new rapid diagnostic test for sleeping sickness was highly sensitive and specific. A negative HAT Sero K-SeT test allows to rule out sleeping sickness in this setting.
Rapid Diagnostic Tests (RDT) are promising tools for clinical management of sleeping sickness or Human African Trypanosomiasis (HAT), as most patients live in remote rural areas in Central or West Africa. We evaluated the HAT Sero-K-SeT, a novel RDT in a series of consecutively enrolled patients with clinical symptoms suggestive of second-stage sleeping sickness. This design is known as phase III in diagnostic accuracy studies, as the patient set is representative of future use of the RDT. The test showed high sensitivity and specificity. We conclude that in such patients, an RDT for HAT should be done. If negative, HAT can be ruled out. If positive, the likelihood of HAT is very high.
Collapse
Affiliation(s)
- Marleen Boelaert
- Institute of Tropical Medicine, Nationalestraat 155, Antwerp B-2000, Belgium.
| | - Deby Mukendi
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
| | - Emmanuel Bottieau
- Institute of Tropical Medicine, Nationalestraat 155, Antwerp B-2000, Belgium.
| | - Jean Roger Kalo Lilo
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of the Congo.
| | - Kristien Verdonck
- Institute of Tropical Medicine, Nationalestraat 155, Antwerp B-2000, Belgium.
| | - Luigi Minikulu
- Hôpital Général de Mosango, Ministry of Health, Democratic Republic of the Congo.
| | - Barbara Barbé
- Institute of Tropical Medicine, Nationalestraat 155, Antwerp B-2000, Belgium.
| | - Philippe Gillet
- Institute of Tropical Medicine, Nationalestraat 155, Antwerp B-2000, Belgium.
| | | | | | - Pascal Lutumba
- Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
| |
Collapse
|
30
|
Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet 2017; 390:2397-2409. [PMID: 28673422 DOI: 10.1016/s0140-6736(17)31510-6] [Citation(s) in RCA: 430] [Impact Index Per Article: 61.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Revised: 03/20/2017] [Accepted: 04/28/2017] [Indexed: 10/19/2022]
Abstract
Human African trypanosomiasis (sleeping sickness) is a parasitic infection that almost invariably progresses to death unless treated. Human African trypanosomiasis caused devastating epidemics during the 20th century. Thanks to sustained and coordinated efforts over the past 15 years, the number of reported cases has fallen to an historically low level. Fewer than 3000 cases were reported in 2015, and the disease is targeted for elimination by WHO. Despite these recent successes, the disease is still endemic in parts of sub-Saharan Africa, where it is a considerable burden on rural communities, most notably in central Africa. Since patients are also reported from non-endemic countries, human African trypanosomiasis should be considered in differential diagnosis for travellers, tourists, migrants, and expatriates who have visited or lived in endemic areas. In the absence of a vaccine, disease control relies on case detection and treatment, and vector control. Available drugs are suboptimal, but ongoing clinical trials provide hope for safer and simpler treatments.
Collapse
Affiliation(s)
- Philippe Büscher
- Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
| | - Giuliano Cecchi
- Food and Agriculture Organization of the United Nations, Sub-regional Office for Eastern Africa, Addis Ababa, Ethiopia
| | - Vincent Jamonneau
- UMR INTERTRYP, Institut de Recherche pour le Développement, Montpellier, France
| | - Gerardo Priotto
- World Health Organization, Control of Neglected Tropical Diseases, Innovative and Intensified Disease Management, Geneva, Switzerland
| |
Collapse
|
31
|
Neglected Tropical Diseases: Epidemiology and Global Burden. Trop Med Infect Dis 2017; 2:tropicalmed2030036. [PMID: 30270893 PMCID: PMC6082091 DOI: 10.3390/tropicalmed2030036] [Citation(s) in RCA: 145] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 07/19/2017] [Accepted: 08/02/2017] [Indexed: 12/22/2022] Open
Abstract
More than a billion people—one-sixth of the world’s population, mostly in developing countries—are infected with one or more of the neglected tropical diseases (NTDs). Several national and international programs (e.g., the World Health Organization’s Global NTD Programs, the Centers for Disease Control and Prevention’s Global NTD Program, the United States Global Health Initiative, the United States Agency for International Development’s NTD Program, and others) are focusing on NTDs, and fighting to control or eliminate them. This review identifies the risk factors of major NTDs, and describes the global burden of the diseases in terms of disability-adjusted life years (DALYs).
Collapse
|
32
|
Rock KS, Torr SJ, Lumbala C, Keeling MJ. Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of Congo. PLoS Negl Trop Dis 2017; 11:e0005162. [PMID: 28056016 PMCID: PMC5215767 DOI: 10.1371/journal.pntd.0005162] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Accepted: 11/04/2016] [Indexed: 01/24/2023] Open
Abstract
Two goals have been set for Gambian human African trypanosomiasis (HAT), the first is to achieve elimination as a public health problem in 90% of foci by 2020, and the second is to achieve zero transmission globally by 2030. It remains unclear if certain HAT hotspots could achieve elimination as a public health problem by 2020 and, of greater concern, it appears that current interventions to control HAT in these areas may not be sufficient to achieve zero transmission by 2030. A mathematical model of disease dynamics was used to assess the potential impact of changing the intervention strategy in two high-endemicity health zones of Kwilu province, Democratic Republic of Congo. Six key strategies and twelve variations were considered which covered a range of recruitment strategies for screening and vector control. It was found that effectiveness of HAT screening could be improved by increasing effort to recruit high-risk groups for screening. Furthermore, seven proposed strategies which included vector control were predicted to be sufficient to achieve an incidence of less than 1 reported case per 10,000 people by 2020 in the study region. All vector control strategies simulated reduced transmission enough to meet the 2030 goal, even if vector control was only moderately effective (60% tsetse population reduction). At this level of control the full elimination threshold was expected to be met within six years following the start of the change in strategy and over 6000 additional cases would be averted between 2017 and 2030 compared to current screening alone. It is recommended that a two-pronged strategy including both enhanced active screening and tsetse control is implemented in this region and in other persistent HAT foci to ensure the success of the control programme and meet the 2030 elimination goal for HAT. Gambian sleeping sickness is a tsetse-transmitted disease which, without treatment, usually results in death. Unfortunately no medical prophylaxis exists to prevent infection in humans but curative medicines and vector control options are available. Recently there has been a push to reduce disease burden and a target incidence of 1 reported case per 10,000 people per year is hoped to be achieved in 90% of regions by 2020. Subsequently there is a goal of zero transmission by 2030. Using mathematical modelling, we assessed how different intervention strategies such as improving screening and treatment or introducing vector control can help in achieving these goals in a high endemicity setting. Following model simulation, we predict that improving current screening can reduce the time taken until the elimination targets are met. However it is very unlikely that the reported case target will by achieved by 2020 without additional vector control. We found that vector control has great potential to reduce transmission and, even if it is less effective at reducing tsetse numbers as in other regions, the full elimination goal could still be achieved by 2030. We recommend that control programmes use a combined medical and vector control strategy to help combat sleeping sickness.
Collapse
Affiliation(s)
- Kat S. Rock
- Warwick Infectious Disease Epidemiology Research (WIDER), The University of Warwick, Coventry, UK
- Life Sciences, The University of Warwick, Coventry, UK
- * E-mail:
| | - Steve J. Torr
- Warwick Infectious Disease Epidemiology Research (WIDER), The University of Warwick, Coventry, UK
- Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK
| | - Crispin Lumbala
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of Congo
| | - Matt J. Keeling
- Warwick Infectious Disease Epidemiology Research (WIDER), The University of Warwick, Coventry, UK
- Life Sciences, The University of Warwick, Coventry, UK
- Mathematics Institute, The University of Warwick, Coventry, UK
| |
Collapse
|
33
|
Stanton MC. The Role of Spatial Statistics in the Control and Elimination of Neglected Tropical Diseases in Sub-Saharan Africa: A Focus on Human African Trypanosomiasis, Schistosomiasis and Lymphatic Filariasis. ADVANCES IN PARASITOLOGY 2017; 97:187-241. [PMID: 28325371 DOI: 10.1016/bs.apar.2017.01.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Disease control and elimination programmes can benefit greatly from accurate information on the spatial variability of disease risk, particularly when risk is highly spatially heterogeneous. Due to advances in statistical methodology, coupled with the increased availability of geospatial technology, this information is becoming increasingly accessible. In this chapter we describe recent advancements in spatial methods associated with the analysis of disease data measured at the point-level and demonstrate their application to the control and elimination of neglected tropical diseases (NTDs). We further provide information on spatially referenced data sources and software that can be used to create NTD risk maps, concentrating on those that can be freely obtained. Examples relating to three NTDs affecting populations in sub-Saharan Africa are presented throughout the chapter, i.e., human African trypanosomiasis, schistosomiasis and lymphatic filariasis. These three diseases, with differing routes of transmission, control methods and level of spatial heterogeneity, demonstrate the flexibility and applicability of the methods described.
Collapse
Affiliation(s)
- M C Stanton
- Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
| |
Collapse
|
34
|
Wamwiri FN, Changasi RE. Tsetse Flies (Glossina) as Vectors of Human African Trypanosomiasis: A Review. BIOMED RESEARCH INTERNATIONAL 2016; 2016:6201350. [PMID: 27034944 PMCID: PMC4789378 DOI: 10.1155/2016/6201350] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Revised: 02/02/2016] [Accepted: 02/04/2016] [Indexed: 11/18/2022]
Abstract
Human African Trypanosomiasis (HAT) transmitted by the tsetse fly continues to be a public health issue, despite more than a century of research. There are two types of the disease, the chronic gambiense and the acute rhodesiense-HAT. Fly abundance and distribution have been affected by changes in land-use patterns and climate. However, disease transmission still continues. Here, we review some aspects of HAT ecoepidemiology in the context of altered infestation patterns and maintenance of the transmission cycle as well as emerging options in disease and vector control.
Collapse
Affiliation(s)
- Florence Njeri Wamwiri
- Kenya Agricultural and Livestock Research Organisation, Biotechnology Research Institute, P.O. Box 362, Muguga 00902, Kenya
| | - Robert Emojong Changasi
- Kenya Agricultural and Livestock Research Organisation, Biotechnology Research Institute, P.O. Box 362, Muguga 00902, Kenya
| |
Collapse
|
35
|
Rock KS, Torr SJ, Lumbala C, Keeling MJ. Quantitative evaluation of the strategy to eliminate human African trypanosomiasis in the Democratic Republic of Congo. Parasit Vectors 2015; 8:532. [PMID: 26490248 PMCID: PMC4618948 DOI: 10.1186/s13071-015-1131-8] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Accepted: 10/02/2015] [Indexed: 12/03/2022] Open
Abstract
Background The virulent vector-borne disease, Gambian human African trypanosomiasis (HAT), is one of several diseases targeted for elimination by the World Health Organization. This article utilises human case data from a high-endemicity region of the Democratic Republic of Congo in conjunction with a suite of novel mechanistic mathematical models to address the effectiveness of on-going active screening and treatment programmes and compute the likely time to elimination as a public health problem (i.e. <1 case per 10,000 per year). Methods The model variants address uncertainties surrounding transmission of HAT infection including heterogeneous risk of exposure to tsetse bites, non-participation of certain groups during active screening campaigns and potential animal reservoirs of infection. Results Model fitting indicates that variation in human risk of tsetse bites and participation in active screening play a key role in transmission of this disease, whilst the existence of animal reservoirs remains unclear. Active screening campaigns in this region are calculated to have been effective, reducing the incidence of new human infections by 52–53 % over a 15-year period (1998–2012). However, projections of disease dynamics in this region indicate that the elimination goal may not be met until later this century (2059–2092) under the current intervention strategy. Conclusions Improvements to active detection, such as screening those who have not previously participated and raising overall screening levels, as well as beginning widespread vector control in the area have the potential to ensure successful and timely elimination. Electronic supplementary material The online version of this article (doi:10.1186/s13071-015-1131-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Kat S Rock
- Life Sciences, Warwick University, Coventry, CV4 7AL, UK. .,WIDER, Warwick University, Coventry, CV4 7AL, UK.
| | - Steve J Torr
- WIDER, Warwick University, Coventry, CV4 7AL, UK.,Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
| | - Crispin Lumbala
- Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, Democratic Republic of Congo
| | - Matt J Keeling
- Life Sciences, Warwick University, Coventry, CV4 7AL, UK.,WIDER, Warwick University, Coventry, CV4 7AL, UK.,Mathematics Institute, Warwick University, Coventry, CV4 7AL, UK
| |
Collapse
|